BMY — Bristol-Myers Squibb Company

Summary of Bristol-Myers Squibb Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Sales: Approximately $12.2 billion, reflecting a 17% year-over-year increase.
• Growth Portfolio: Sales increased 17%, driven by strong demand for products like Opdivo, Reblozyl, Camzyos, and Breyanzi.
• Opdivo Sales: $2.5 billion, up 6%, with growth from new indications.
• Reblozyl Sales: $615 million, up 38%, primarily in the U.S.
• Breyanzi Sales: $359 million, growing 58%.
• Camzyos Sales: $296 million, up 88%.
• Eliquis Sales: $3.7 billion, growing 23%.
• Diluted EPS: $1.63, impacted by net charges of approximately $530 million.
• Gross Margin: Approximately 73%.
• Cash Flow from Operations: About $6.3 billion, with nearly $17 billion in cash and equivalents as of September 30.

2. Strategic Updates and Business Highlights

• Product Launches: Cobenfy and Qvantig are performing well, with Cobenfy achieving steady growth and positive physician feedback.
• Clinical Milestones: Positive results from the Phase III EXCALIBER study for Iberdomide in multiple myeloma and advancements in the protein degradation platform.
• Acquisitions: Acquired Orbital Therapeutics to enhance the cell therapy franchise and closed a licensing agreement with PhiloChem for a radiopharmaceutical agent.
• Manufacturing Hub: Opened a U.S. manufacturing facility for rapid delivery of radiopharmaceutical therapies.
• Pipeline Development: Anticipating data readouts for multiple new molecular entities and life cycle management opportunities over the next 12-24 months.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased by $750 million to a range of $47.5 billion to $48 billion for 2025, reflecting strong growth portfolio performance.
• EPS Guidance: Narrowed to between $6.40 and $6.60, with the midpoint unchanged.
• Cost Management: Continued focus on strategic productivity initiatives, targeting $2 billion in savings by 2027.
• Long-term Growth: Potential to introduce 10 new medicines and 30 significant life cycle management opportunities by the end of the decade.

4. Bad News, Challenges, or Points of Concern

• Legacy Portfolio Decline: Expected to decline approximately 15% to 17% for the year, with Revlimid sales anticipated at around $3 billion.
• Competitive Pressures: Increased scrutiny on the ADEPT-2 study and potential challenges in the PD-1/VEGF space.
• Regulatory Risks: Ongoing discussions regarding IRA negotiations for Pomalyst, with price controls expected to impact future revenues.
• Market Dynamics: Need for continued education and adoption of new products like Cobenfy in a competitive market.

5. Notable Q&A Insights

• ADEPT-2 Study: Confidence remains in the Cobenfy program, with data expected by year-end. No additional comments on site irregularities or patient additions.
• Cobenfy Commercialization: Positive feedback from physicians, but ongoing efforts are needed to increase prescribing depth and breadth.
• Milvexian Development: Confidence in the drug's profile and differentiation from competitors, with an accelerated readout timeline for atrial fibrillation.
• Policy Environment: Active engagement with the administration on pricing policies, with constructive discussions ongoing.
• Pipeline Priorities: Focus on integrating new technologies and enhancing development processes, particularly in protein degradation and cell therapy.

This summary encapsulates the key aspects of Bristol-Myers Squibb's Q3 2025 earnings call, highlighting both positive developments and areas of concern as the company navigates its growth trajectory.